Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer.

The addition of everolimus to letrozole leads to a highly significant (90%) reduction in Ki67 expression after 16 weeks of treatment, particularly in patients with tumors harboring a mutation in exon 9 of PIK3CA, while the variation is minimal in cases of mutations in exon 20 or the wild-type form [ 113 ].

also in 132,142 other papers